GABA is the primary inhibitory neurotransmitter in the brain. When it binds to GABA-A receptors, chloride ions flow into the neuron and make that neuron less likely to fire. This is one of the brain's most important balancing systems. Without enough inhibition, excitatory circuits can run unchecked.

That is why the GABA system is central to anxiety, arousal control, seizure prevention, and overall excitatory-inhibitory balance. It is not just a sleep system or just an anxiolytic system; it is core neural infrastructure.

GABA-A receptors are not all identical. They are pentameric receptors assembled from different α, β, γ, δ, and other subunit families. The exact combination changes the receptor's behavior and pharmacology. Benzodiazepines, for example, bind at specific interfaces that depend on the subunit arrangement present.

This is the key reason Selank is interesting. It is studied not as a direct receptor-binding sedative, but as a regulator of GABA-A subunit gene expression. In other words, it may change which versions of the receptor are built, rather than simply pushing the existing receptors harder.

Benzodiazepines directly modulate the receptor at the protein level and can quickly produce tolerance and dependence issues. Selank is studied as a transcriptional modulator that changes the architecture of inhibitory signaling more indirectly. That does not make it better by default, but it does make it mechanistically distinct.

Understanding the GABA system helps clarify why two anxiolytic strategies can look similar at the outcome level while intervening at entirely different biological layers.